hepacult was established as a spin-off from the University of Regensburg in 2002. The entrepreneur team has developed a technology platform for the isolation, cultivation and preservation of human liver cells. Based on this know-how resources a series of innovative products and services has been generated to provide the pharmaceutical industry and scientific community with cutting edge solutions for their specific problems.

Human liver cells for applied sciences and pharma research

hepacult offers in vitro systems, generated out of human liver tissue. The liver is the central metabolic organ for substances like drugs. The scientific community sees cells from the human liver as the silver bullet to test effects of a medication on human metabolism thouroughly.

hepacult is supplier and service partner of the pharmaceutical industry and scientific community.

hepacult facilitates the substitution of animal experiments partially, reduces the risk of adverse effects of novel drugs and provides research with a cutting edge in vitro model, surpassing competing products in terms of quality and price.

Innovative technologies protect the donor material

hepacult deploys preservation techniques which do not have a negative impact on the quality of the material.

hepacult is dedicated to the incessant strive for technological enhancement to create standardized and validated conditions for industry and science.

Regenerative medicine and novel therapies

hepacult pursues the development of new fields of application for their proprietary technologies. The know-how will be transferred to other organs and tissues of the human body.

hepacult works together with partners on novel concepts for the regeneration of liver cell tissue and on new therapeutic approaches in areas like hepatology, virology and transplantation medicine.